FDA Denies Majority Of Requests To Reclassify Low-Risk De Novo Devices
This article was originally published in The Gray Sheet
Close to 63% of requests to FDA seeking Class I or Class II status for de novo devices without a predicate have been denied to date, FDA staffers say.
You may also be interested in...
FDA may indicate in future "not substantially equivalent" 510(k) letters whether or not the sponsor's device is a likely candidate for placement in Class I or Class II using the new alternative low-risk de novo device classification process established by Sec. 207 of the FDA Modernization Act.
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.